Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics

The current high mortality of human lung cancer stems largely from the lack of feasible, early disease detection tools. An effective test with serum metabolomics predictive models able to suggest patients harboring disease could expedite triage patient to specialized imaging assessment. Here, using...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2021-12, Vol.118 (51)
Main Authors: Schult, Tjada A, Lauer, Mara J, Berker, Yannick, Cardoso, Marcella R, Vandergrift, Lindsey A, Habbel, Piet, Nowak, Johannes, Taupitz, Matthias, Aryee, Martin, Mino-Kenudson, Mari A, Christiani, David C, Cheng, Leo L
Format: Article
Language:English
Subjects:
Aged
Biological Sciences
Diagnosis
Disease detection
Early Detection of Cancer - methods
Female
Humans
Lung cancer
Lung diseases
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - metabolism
Magnetic Resonance Spectroscopy
Male
Medical diagnosis
Metabolic Networks and Pathways
Metabolomics
Middle Aged
Patients
Prediction models
Predictive control
Predictive Value of Tests
Reproducibility of Results
Resonance
Spectroscopy
Spectrum analysis
Survival
Training
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current high mortality of human lung cancer stems largely from the lack of feasible, early disease detection tools. An effective test with serum metabolomics predictive models able to suggest patients harboring disease could expedite triage patient to specialized imaging assessment. Here, using a training-validation-testing-cohort design, we establish our high-resolution magic angle spinning (HRMAS) magnetic resonance spectroscopy (MRS)-based metabolomics predictive models to indicate lung cancer presence and patient survival using serum samples collected prior to their disease diagnoses. Studied serum samples were collected from 79 patients before (within 5.0 y) and at lung cancer diagnosis. Disease predictive models were established by comparing serum metabolomic patterns between our training cohorts: patients with lung cancer at time of diagnosis, and matched healthy controls. These predictive models were then applied to evaluate serum samples of our validation and testing cohorts, all collected from patients before their lung cancer diagnosis. Our study found that the predictive model yielded values for prior-to-detection serum samples to be intermediate between values for patients at time of diagnosis and for healthy controls; these intermediate values significantly differed from both groups, with an F1 score = 0.628 for cancer prediction. Furthermore, values from metabolomics predictive model measured from prior-to-diagnosis sera could significantly predict 5-y survival for patients with localized disease.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.2110633118